Xanthomas of the Tendon

Overview

Xanthomas of the tendon are firm, yellow‑orange nodules that develop within or on the surface of tendons, most commonly the Achilles tendon, extensor tendons of the hands, and the patellar tendon. They are composed of lipid‑laden macrophages (foam cells) that accumulate in the connective tissue. Tendon xanthomas are strongly associated with disorders of lipid metabolism, especially familial hypercholesterolemia (FH), but can also appear in other hyperlipidemic states.

Who it affects: The condition is most prevalent in adolescents and young adults with genetically inherited lipid disorders, particularly males (a 2‑3:1 male‑to‑female ratio). In the United States, FH affects about 1 in 250 people; up to 20‑30 % of these individuals develop tendon xanthomas during their lifetime (Mayo Clinic, 2023).

Prevalence: While isolated tendon xanthomas are rare in the general population (<0.1 %), they serve as a visible marker for underlying severe hyperlipidemia. In European registries of FH, tendon xanthomas are reported in 13‑25 % of patients, making them one of the most recognizable clinical signs of the disease (EAS Familial Hypercholesterolemia Study Group, 2022).

Symptoms

Tendon xanthomas are usually painless, but they may cause functional problems depending on size and location. Common symptoms include:

• Visible nodules: Yellow‑orange, firm plaques that may be several millimetres to centimetres in diameter. Often most noticeable on the Achilles tendon, the dorsum of the hands (extensor tendons), and the patellar tendon.
• Palpable thickening: The tendon feels thicker or hard when pressed.
• Reduced tendon flexibility: Large lesions can limit the range of motion, especially in the ankle (Achilles) or fingers (extensor tendons).
• Discomfort or aching: Rarely, pressure from the nodule can cause mild pain during activity or after prolonged standing.
• Cosmetic concern: The yellowish colour and swelling can be distressing, especially in visible areas like the hands.
• Associated symptoms of underlying lipid disorder: premature coronary artery disease, xanthelasma (eyelid plaques), and corneal arcus.

Causes and Risk Factors

Primary cause – lipid metabolism disorders

Tendon xanthomas are most often the cutaneous manifestation of familial hypercholesterolemia (FH), an autosomal‑dominant condition caused by mutations in the LDLR, APOB, or PCSK9 genes. These mutations impair clearance of low‑density lipoprotein (LDL) cholesterol, leading to chronically elevated LDL‑C levels (often >190 mg/dL in heterozygous FH).

Other lipid disorders

• Familial combined hyperlipidemia
• Familial Lp(a) hyperlipoproteinemia
• Secondary hyperlipidemia due to uncontrolled diabetes, hypothyroidism, or nephrotic syndrome

Non‑lipid related causes (rare)

• Vasculitis or inflammatory diseases that cause lipid‑rich macrophage infiltration
• Medication‑induced dyslipidemia (e.g., certain antiretrovirals, protease inhibitors)

Risk factors

• Genetic inheritance of FH (first‑degree relative with confirmed FH)
• Male sex
• Early‑onset coronary artery disease (<45 y in men, <55 y in women)
• Smoking, obesity, and sedentary lifestyle (exacerbate lipid levels)
• Untreated or poorly controlled diabetes mellitus

Diagnosis

Diagnosing tendon xanthomas involves a combination of clinical examination, imaging, and laboratory evaluation.

1. Clinical examination

• Inspection for yellow‑orange plaques over tendons.
• Palpation to assess firmness and size.
• Evaluation of tendon function (range of motion, strength).

2. Imaging studies

• Ultrasound: First‑line, non‑invasive; shows hyperechoic, well‑defined nodules within the tendon. Sensitivity >90 % for detecting tendon xanthomas (Radiology Society of North America, 2021).
• Magnetic Resonance Imaging (MRI): Provides detailed soft‑tissue contrast; lesions appear as low‑signal intensity on T1/T2 due to lipid‑laden foam cells.
• CT scan: Rarely needed; can demonstrate calcification in chronic lesions.

3. Laboratory tests

• Lipid panel: total cholesterol, LDL‑C, HDL‑C, triglycerides.
• Apolipoprotein B and Lipoprotein(a) (Lp(a)) levels for comprehensive risk stratification.
• Genetic testing for FH mutations (recommended when LDL‑C >190 mg/dL and/or tendon xanthomas are present).

4. Differential diagnosis

Other conditions that can mimic tendon xanthomas include:

• Gouty tophi
• Dermatofibromas
• Rheumatoid nodules
• Calcific tendinitis

Treatment Options

Management focuses on two goals: eliminating the underlying lipid abnormality and addressing the local tendon lesions.

1. Lipid‑lowering medications

• Statins (e.g., atorvastatin, rosuvastatin): First‑line; lower LDL‑C by 30‑50 %. High‑intensity statin therapy is recommended in FH (ACC/AHA Guideline, 2018).
• Ezetimibe: Added when LDL‑C target not reached with statins alone; provides an extra 15‑20 % reduction.
• PCSK9 inhibitors (evolocumab, alirocumab): Useful in severe FH; can reduce LDL‑C >60 % and have been shown to regress tendon xanthomas over 2‑3 years (J Am Coll Cardiol, 2020).
• Bile‑acid sequestrants, fibrates, or niacin: Considered in selected patients with mixed hyperlipidemia.

2. Lifestyle modifications

• Adopt a heart‑healthy diet (Mediterranean or DASH) low in saturated fat, trans fat, and cholesterol.
• Consume 25‑30 g of soluble fiber daily (oats, barley, legumes) to aid cholesterol reduction.
• Engage in at least 150 minutes of moderate‑intensity aerobic exercise per week.
• Weight management: aim for BMI < 25 kg/m².
• Smoking cessation – smoking doubles cardiovascular risk in FH.

3. Surgical and procedural options

Local removal is rarely required but may be considered when:

• Lesions cause functional impairment (e.g., tendon rupture risk).
• Cosmetic concerns are significant for the patient.

Procedures include:

• Excisional surgery: Complete removal of the xanthoma with careful tendon repair. Requires a hand or orthopedic specialist.
• Laser‑assisted ablation: Emerging technique with limited data; may reduce lesion size without extensive tissue loss.
• Dermabrasion or curettage: Used for superficial plaques on the hand.

Note: Surgical removal does not treat the underlying lipid disorder; lesions may recur if lipid levels remain uncontrolled.

4. Monitoring and follow‑up

• Repeat lipid panel every 3‑6 months until target LDL‑C is achieved, then annually.
• Ultrasound assessment of tendon xanthomas every 1–2 years to gauge regression.
• Cardiovascular risk assessment (coronary calcium score, stress testing) as indicated.

Living with Xanthomas of the Tendon

Daily management tips

• Footwear: Choose supportive shoes with good cushioning to reduce stress on the Achilles tendon.
• Hand care: If extensor tendon xanthomas affect grip, use ergonomic tools and consider splints during activities that cause discomfort.
• Skin hygiene: Keep the area clean and moisturized; avoid vigorous scrubbing that could irritate the lesion.
• Regular exercise: Low‑impact activities (swimming, cycling) protect tendons while still improving lipid profile.
• Medication adherence: Set daily reminders; use a pill organizer; discuss any side effects with your provider promptly.
• Family screening: Encourage first‑degree relatives to undergo lipid testing and genetic counseling.

Psychosocial aspects

Visible xanthomas can affect body image and self‑esteem. Consider:

• Support groups for FH (e.g., FH Foundation community).
• Referral to a mental‑health professional if anxiety or depression develops.
• Educational materials to help friends and coworkers understand the condition.

Prevention

Because most tendon xanthomas stem from inherited lipid disorders, primary prevention focuses on early detection and aggressive lipid control.

• Screening: Lipid panel for all children with a family history of premature heart disease or known FH, starting at age 2‑9 (CDC, 2022).
• Genetic counseling: Offer to families with a confirmed FH mutation.
• Lifestyle: Healthy diet and regular activity from childhood minimize secondary lipid elevations.
• Medication when indicated: Statin therapy can be initiated in FH children as young as 8‑10 years under specialist supervision.

Complications

If left untreated, tendon xanthomas are more than a cosmetic issue.

• Cardiovascular disease: FH patients with tendon xanthomas have a 3‑5‑fold higher risk of premature myocardial infarction (NIH, 2021).
• Tendon rupture: Large, infiltrative xanthomas weaken tendon fibers, increasing the chance of rupture, especially in the Achilles tendon.
• Functional limitation: Reduced range of motion can impair walking, running, or fine motor tasks.
• Recurrence after surgery: Without lipid control, new xanthomas frequently appear at the same or different tendons.

When to Seek Emergency Care

Key Take‑aways

• Tendon xanthomas are a visible marker of severe hyperlipidemia, most often familial hypercholesterolemia.
• Diagnosis combines physical exam, ultrasound/MRI, lipid studies, and often genetic testing.
• Aggressive lipid‑lowering therapy (high‑intensity statins ± PCSK9 inhibitors) can shrink or even eliminate xanthomas over time.
• Lifestyle changes and family screening are essential components of long‑term management.
• Early detection and treatment dramatically reduce the risk of premature cardiovascular disease.

For personalized advice, schedule an appointment with a lipid specialist, cardiologist, or dermatologist experienced in metabolic skin disorders.